A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses

Archives of Dermatology

Volumn 138, Issue 11, 2002, Pages 1498-1502

  Stockfleth, Eggert ^a   Meyer, Thomas ^a   Benninghoff, Bernd ^a   Salasche, Stuart ^a   Papadopoulos, Latza ^a   Ulrich, Claas ^a   Christophers, Enno ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EROSION; ERYTHEMA; FEMALE; GERMANY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN DEFECT; SKIN INDURATION; SKIN ULCER;

EID: 0036845121     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.138.11.1498     Document Type: Article

References (18)

1. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327:1649-1662.
2. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol. 1999;41:443-448.
3. Dodson JM, de Spain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: A patient-oriented perspective. Arch Dermatol. 1991;127:1029-1031.
4. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma I. J Am Acad Dermatol. 2000;42(1, pt 2):4-7.
5. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42(1, pt 2):25-28.
6. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol. 1998;134:25-30.
7. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of 6 cases. Br J Dermatol. 2001;144:1050-1058.
8. Stanley MA. Mechanism of action of imiquimod. Papillomavirus Rep. 1999;10(2):23-29
9. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier 5% imiquimod cream. J Am Acad Dermatol. 1999;41:1002-1007.
10. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 2001;44:462-470.
11. Ahmed I, Berth-Jones J. Imiquimod: A novel treatment for lentigo maligna. Br J Dermatol. 2000;143:843-45.
12. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol. 1999;135:1167-1169.
13. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. 2000;143:1026-1031.
14. Stockfleth E, Röwert J, Arndt R, Meyer T, Christophers E. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol. 2000;143:846-850.
15. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147-1151.
16. Tyring SK. Immune response modifiers: A new paradigm in the treatment of human papillomavirus. Curr Ther Res Clin Exp. 2000;61:584-596.
17. Wong DA, Bishop GA, Lowes MA, Cooke B, Barnetson RS, Halliday GM. Cytokine profiles in spontaneously regressing basal cell carcinomas. Br J Dermatol. 2000;143:91-98.
18. Kagy MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26:577-579.